illumigene® Malaria is more widely used than it was a year ago, but Meridian Bioscience says even more countries should use it." Researchers in Europe and philanthropists in New York are singing the ...

Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada. C. difficile is a bacterium that can cause symptoms ranging from ...

Diagnostic test kit maker Meridian Bioscience (VIVO) has won the approval of the U.S. Food and Drug Administration (:FDA) for its new test for detection of Legionnaire’s disease (legionellosis), a ...

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received Australian regulatory clearance of a molecular test for group B streptococcus. The test is part of Cincinnati-area Meridian’s ...

Newtown-based Meridian Bioscience is deploying its newly developed test illumigene® Malaria in Dakar, Senegal and planning a rollout of this potentially life-saving diagnostic across Africa. A test ...

Meridian Bioscience (VIVO) is a $900 million provider of diagnostic test kits for gastrointestinal and respiratory infectious diseases. The company is expected to grow sales 18% this year to $300 ...

Researchers in Europe and philanthropists in New York are singing the praises Tuesday of a new malaria test from Newtown-based Meridian Bioscience on this World Malaria Day. The company's extremely ...